Abbott Laboratories said Thursday it has started a trial assessing the safety and effectiveness of its investigational Cephea mitral valve system to treat people with mitral valve disease who are... Medical Equipment, Supplies & Distribution Abbott Laboratories Starts Trial for Device…
Abbott received U.S. Food and Drug Administration approval for the Amplatzer Paraclose PVL Occluder, the first and only transcatheter device approved in the U.S. that is specifically designed to treat... Food and Drug Administration approval for the Amplatzer Paraclose PVL Occluder, the…
Ghana is exploring local and regional production of HIV medicines and other essential health commodities to reduce dependence on international supply chains and strengthen the sustainability of its national HIV response. The initiative is intended to protect the country’s access…
Oct 01, 2026, 10:00 ET NORTH CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week…
Tune in for the latest research and perspectives on kidney health from NKF. Answer a few questions and we will provide you with information about your kidney health. Learn about the basics of kidney disease, how it is measured, and…
Their AAV progranulin included a C-terminal Myc tag for tracking the exogenous protein in the brain. This tag also happened to block sortilin binding. Regardless, the protein made its way into neuronal and microglial lysosomes, where it restored normal function.
Lakewood-Amedex Biotherapeutics Inc. announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigated... announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu…
Lakewood-Amedex Biotherapeutics Inc: Lakewood-Amedex Biotherapeutics announces positive data for the advancement of lead candidate, Nu-3, in infected diabetic foot ulcers Lakewood-Amedex... Biotechnology & Medical Research Lakewood-Amedex Biotherapeutics announces positive data for the advancement of lead candidate, Nu-3 Published on 05/18/2026 at 09:38 am…
Lakewood-Amedex Biotherapeutics Inc. announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly... announced positive data for its lead compound, Nu-3, as it advances…
Lakewood-Amedex Biotherapeutics Inc: Lakewood-Amedex Biotherapeutics announces agreement with PERI to serve as CRO for Phase 2 clinical trial of Nu-3... Biotechnology & Medical Research Lakewood-Amedex Biotherapeutics announces agreement with PERI to serve as CRO for Phase 2 clinical trial of Nu-3 Published on…
Pipelines, trials, approvals, safety, manufacturing, and next‑gen therapies.
An article joins this feed when it matches these terms. Each one is also a search of its own.